Format

Send to

Choose Destination
Sci Rep. 2018 Feb 1;8(1):2040. doi: 10.1038/s41598-018-20349-6.

Possible role of chondroitin sulphate and glucosamine for primary prevention of colorectal cancer. Results from the MCC-Spain study.

Author information

1
Unit of Biomarkers and Susceptibility, Cancer Prevention and Control Programme, Catalan Institute of Oncology-IDIBELL, L'Hospitalet de Llobregat, Spain.
2
Gastroenterology Department, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, Spain.
3
Grupo de Investigación en Interacciones Gen-Ambiente y Salud, Universidad de León, León, Spain.
4
CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
5
ISGlobal Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain.
6
Universitat Pompeu Fabra (UPF), Barcelona, Spain.
7
Environmental and Cancer Epidemiology Department, National Centre of Epidemiology - Instituto de Salud Carlos III, Madrid, Spain.
8
Oncology and Hematology Area, IIS Puerta De Hierro, Cancer Epidemiology Research Group, Madrid, Spain.
9
Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Servicio Andaluz de Salud/Universidad de Granada, Granada, Spain.
10
Departamento de Medicina Preventiva y Salud Pública, Universidad de Granada, Granada, Spain.
11
Universidad de Cantabria - IDIVAL, Santander, Spain.
12
Navarra Public Health Institute, Pamplona, Spain.
13
IdiSNA, Navarra Institute for Health Research, Pamplona, Spain.
14
Public Health Division of Gipuzkoa, Biodonostia Research Institute, San Sebastian, Spain.
15
La Fe University and Politechnic Hospital, Health Research Institute La Fe, Valencia, Spain.
16
CIBER Enfermedades hepáticas y digestivas (CIBEREHD), Madrid, Spain.
17
University Institute of Oncology of Asturias (IUOPA), Universidad de Oviedo, Oviedo, Spain.
18
Juan Ramon Jiménez University Hospital, University of Huelva, Huelva, Spain.
19
Centre for Research in Health and Environment (CYSMA), University of Huelva, Huelva, Spain.
20
Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca and Department of Health and Social Sciences, Universidad de Murcia, Murcia, Spain.
21
IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.
22
Unidad de Gestión de Cirugía. Complejo Hospitalario Universitario de Granada, Granada, Spain.
23
Department of Statistics and O. R., Public University of Navarre, Navarre, Spain.
24
Gastroenterology Department, Complejo Asistencial Universitario de León, León, Spain.
25
School of Public Health, Athens, Greece.
26
Unit of Biomarkers and Susceptibility, Cancer Prevention and Control Programme, Catalan Institute of Oncology-IDIBELL, L'Hospitalet de Llobregat, Spain. v.moreno@iconcologia.net.
27
CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. v.moreno@iconcologia.net.
28
Department of Clinical Sciences, Faculty of Medicine, University of Barcelona, Barcelona, Spain. v.moreno@iconcologia.net.

Abstract

A safe and effective colorectal cancer (CRC) chemoprevention agent remains to be discovered. We aim to evaluate the association between the use of glucosamine and/or chondroitin sulphate and risk of colorectal cancer (CRC) in the MCC-Spain study, a case-control study performed in Spain that included 2140 cases of CRC and 3950 population controls. Subjects were interviewed on sociodemographic factors, lifestyle, family and medical history and regular drug use. Adjusted odds ratios and their 95% confidence intervals were estimated. The reported frequency of chondroitin and/or glucosamine use was 2.03% in controls and 0.89% in cases. Users had a reduced risk of CRC (OR: 0.47; 95% CI: 0.28-0.79), but it was no longer significant when adjusted for NSAID (nonsteroidal anti-inflammatory drugs) use (OR: 0.82; 95% CI: 0.47-1.40). A meta-analysis with previous studies suggested a protective effect, overall and stratified by NSAID use (OR: 0.77; 95% CI: 0.62-0.97). We have not found strong evidence of an independent preventive effect of CG on CRC in our population because the observed effects of our study could be attributed to NSAIDs concurrent use. These results merit further research due to the safety profile of these drugs.

PMID:
29391578
PMCID:
PMC5794904
DOI:
10.1038/s41598-018-20349-6
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center